{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T12:35:14Z","timestamp":1791549314953,"version":"4.3.4"},"reference-count":121,"publisher":"Wiley","issue":"8","license":[{"start":{"date-parts":[[2022,2,28]],"date-time":"2022-02-28T00:00:00Z","timestamp":1646006400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004336","name":"Novartis","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004336","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Allergy"],"published-print":{"date-parts":[[2022,8]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Bruton's tyrosine kinase (BTK), a member of the Tec kinase family, is critically involved in a range of immunological pathways. The clinical application of BTK inhibitors for B\u2010cell malignancies has proven successful, and there is strong rationale for the potential benefits of BTK inhibitors in some autoimmune and allergic conditions, including immune\u2010mediated dermatological diseases. However, the established risk\u2010to\u2010benefit profile of \u201cfirst\u2010generation\u201d BTK inhibitors cannot be extrapolated to these emerging, non\u2010oncological, indications. \u201cNext\u2010generation\u201d BTK inhibitors such as remibrutinib and fenebrutinib entered clinical development for chronic spontaneous urticaria (CSU); rilzabrutinib and tirabrutinib are being studied as potential treatments for pemphigus. Promising data from early\u2010phase clinical trials in CSU suggest potential for these agents to achieve strong pathway inhibition, which may translate into measurable clinical benefits, as well as other effects such as the disruption of autoantibody production. BTK inhibitors may help to overcome some of the shortcomings of monoclonal antibody treatments for immune\u2010mediated dermatological conditions such as CSU, pemphigus, and systemic lupus erythematosus. In addition, the use of BTK inhibitors may improve understanding of the pathophysiological roles of mast cells, basophils, and B cells in such conditions.<\/jats:p>","DOI":"10.1111\/all.15261","type":"journal-article","created":{"date-parts":[[2022,2,17]],"date-time":"2022-02-17T11:00:54Z","timestamp":1645095654000},"page":"2355-2366","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":97,"title":["Bruton's tyrosine kinase inhibition\u2014An emerging therapeutic strategy in immune\u2010mediated dermatological conditions"],"prefix":"10.1111","volume":"77","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2439-920X","authenticated-orcid":false,"given":"Pedro","family":"Mendes\u2010Bastos","sequence":"first","affiliation":[{"name":"Dermatology Center Hospital CUF Descobertas  Lisbon Portugal"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8359-6561","authenticated-orcid":false,"given":"Ana","family":"Brasileiro","sequence":"additional","affiliation":[{"name":"Department of Dermatology Hospital Santo Ant\u00f3nio dos Capuchos Centro Hospitalar Universit\u00e1rio Lisboa Central  Lisbon Portugal"},{"name":"NOVA Medical School Universidade NOVA de Lisboa  Lisbon Portugal"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5380-8132","authenticated-orcid":false,"given":"Pavel","family":"Kolkhir","sequence":"additional","affiliation":[{"name":"Dermatological Allergology, Allergie\u2010Centrum\u2010Charit\u00e9, Department of Dermatology and Allergy, Charit\u00e9\u2010Universit\u00e4tsmedizin Berlin, Corporate Member of Freie Universit\u00e4t Berlin Humboldt\u2010Universit\u00e4t zu Berlin, and Berlin Institute of Health  Berlin Germany"},{"name":"Division of Immune\u2010Mediated Skin Diseases I.M. Sechenov First Moscow State Medical University (Sechenov University)  Moscow Russia"},{"name":"Fraunhofer Institute for Translational Medicine and Pharmacology ITMP, Allergology and Immunology  Berlin Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3971-7343","authenticated-orcid":false,"given":"Stefan","family":"Frischbutter","sequence":"additional","affiliation":[{"name":"Dermatological Allergology, Allergie\u2010Centrum\u2010Charit\u00e9, Department of Dermatology and Allergy, Charit\u00e9\u2010Universit\u00e4tsmedizin Berlin, Corporate Member of Freie Universit\u00e4t Berlin Humboldt\u2010Universit\u00e4t zu Berlin, and Berlin Institute of Health  Berlin Germany"},{"name":"Fraunhofer Institute for Translational Medicine and Pharmacology ITMP, Allergology and Immunology  Berlin Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00f6rg","family":"Scheffel","sequence":"additional","affiliation":[{"name":"Dermatological Allergology, Allergie\u2010Centrum\u2010Charit\u00e9, Department of Dermatology and Allergy, Charit\u00e9\u2010Universit\u00e4tsmedizin Berlin, Corporate Member of Freie Universit\u00e4t Berlin Humboldt\u2010Universit\u00e4t zu Berlin, and Berlin Institute of Health  Berlin Germany"},{"name":"Fraunhofer Institute for Translational Medicine and Pharmacology ITMP, Allergology and Immunology  Berlin Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3775-2989","authenticated-orcid":false,"given":"Sherezade","family":"Mo\u00f1ino\u2010Romero","sequence":"additional","affiliation":[{"name":"Dermatological Allergology, Allergie\u2010Centrum\u2010Charit\u00e9, Department of Dermatology and Allergy, Charit\u00e9\u2010Universit\u00e4tsmedizin Berlin, Corporate Member of Freie Universit\u00e4t Berlin Humboldt\u2010Universit\u00e4t zu Berlin, and Berlin Institute of Health  Berlin Germany"},{"name":"Fraunhofer Institute for Translational Medicine and Pharmacology ITMP, Allergology and Immunology  Berlin Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4121-481X","authenticated-orcid":false,"given":"Marcus","family":"Maurer","sequence":"additional","affiliation":[{"name":"Dermatological Allergology, Allergie\u2010Centrum\u2010Charit\u00e9, Department of Dermatology and Allergy, Charit\u00e9\u2010Universit\u00e4tsmedizin Berlin, Corporate Member of Freie Universit\u00e4t Berlin Humboldt\u2010Universit\u00e4t zu Berlin, and Berlin Institute of Health  Berlin Germany"},{"name":"Fraunhofer Institute for Translational Medicine and Pharmacology ITMP, Allergology and Immunology  Berlin Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2022,2,28]]},"reference":[{"key":"e_1_2_9_2_1","doi-asserted-by":"publisher","DOI":"10.1542\/peds.9.6.722"},{"key":"e_1_2_9_3_1","doi-asserted-by":"publisher","DOI":"10.1038\/361226a0"},{"key":"e_1_2_9_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/0092-8674(93)90667-F"},{"key":"e_1_2_9_5_1","doi-asserted-by":"publisher","DOI":"10.1126\/science.8332900"},{"key":"e_1_2_9_6_1","doi-asserted-by":"publisher","DOI":"10.1126\/science.8332901"},{"key":"e_1_2_9_7_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1004594107"},{"key":"e_1_2_9_8_1","doi-asserted-by":"publisher","DOI":"10.1186\/ar3400"},{"key":"e_1_2_9_9_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrc3702"},{"key":"e_1_2_9_10_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2013-204143"},{"key":"e_1_2_9_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2006.11.012"},{"issue":"3","key":"e_1_2_9_12_1","first-page":"945","article-title":"Bruton's Tyrosine Kinase is involved in innate and adaptive immunity","volume":"20","author":"Brunner C","year":"2005","journal-title":"Histol Histopathol"},{"key":"e_1_2_9_13_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-018-0779-z"},{"key":"e_1_2_9_14_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41423-019-0270-9"},{"key":"e_1_2_9_15_1","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M112.372425"},{"key":"e_1_2_9_16_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-04-281170"},{"key":"e_1_2_9_17_1","doi-asserted-by":"publisher","DOI":"10.1111\/all.13166"},{"key":"e_1_2_9_18_1","doi-asserted-by":"publisher","DOI":"10.1615\/CritRevImmunol.v29.i4.30"},{"key":"e_1_2_9_19_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2012.42.7906"},{"key":"e_1_2_9_20_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-014-0178-8"},{"key":"e_1_2_9_21_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-020-01072-6"},{"key":"e_1_2_9_22_1","doi-asserted-by":"publisher","DOI":"10.1080\/14728214.2020.1822817"},{"key":"e_1_2_9_23_1","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2021.668131"},{"key":"e_1_2_9_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cellsig.2010.03.001"},{"key":"e_1_2_9_25_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.91.22.10606"},{"key":"e_1_2_9_26_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-065X.2008.00742.x"},{"key":"e_1_2_9_27_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.94.21.11526"},{"key":"e_1_2_9_28_1","doi-asserted-by":"publisher","DOI":"10.1126\/science.271.5250.822"},{"key":"e_1_2_9_29_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1074-7613(00)80417-3"},{"issue":"12","key":"e_1_2_9_30_1","first-page":"1737","article-title":"SLP\u201076 deficiency impairs signaling via the high\u2010affinity IgE receptor in mast cells","volume":"103","author":"Pivniouk VI","year":"1999","journal-title":"J Clin Invest"},{"key":"e_1_2_9_31_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1074-7613(00)80591-9"},{"key":"e_1_2_9_32_1","doi-asserted-by":"publisher","DOI":"10.1084\/jem.184.1.31"},{"key":"e_1_2_9_33_1","doi-asserted-by":"publisher","DOI":"10.1586\/1744666X.2016.1152888"},{"key":"e_1_2_9_34_1","doi-asserted-by":"publisher","DOI":"10.1002\/cti2.1295"},{"key":"e_1_2_9_35_1","doi-asserted-by":"publisher","DOI":"10.1186\/ar3908"},{"key":"e_1_2_9_36_1","doi-asserted-by":"publisher","DOI":"10.1615\/CritRevImmunol.2018025184"},{"key":"e_1_2_9_37_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40521-021-00286-y"},{"key":"e_1_2_9_38_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2010.12.018"},{"key":"e_1_2_9_39_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2017.03.013"},{"key":"e_1_2_9_40_1","doi-asserted-by":"publisher","DOI":"10.1111\/cts.13005"},{"key":"e_1_2_9_41_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1742-4658.2011.08073.x"},{"key":"e_1_2_9_42_1","doi-asserted-by":"publisher","DOI":"10.1111\/all.14254"},{"key":"e_1_2_9_43_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbamcr.2019.118622"},{"key":"e_1_2_9_44_1","doi-asserted-by":"publisher","DOI":"10.4049\/immunohorizons.2100063"},{"key":"e_1_2_9_45_1","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M115.687251"},{"key":"e_1_2_9_46_1","doi-asserted-by":"publisher","DOI":"10.1111\/all.13397"},{"key":"e_1_2_9_47_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.19561"},{"key":"e_1_2_9_48_1","doi-asserted-by":"publisher","DOI":"10.1111\/all.14037"},{"key":"e_1_2_9_49_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1398-9995.2010.02496.x"},{"key":"e_1_2_9_50_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1900408"},{"key":"e_1_2_9_51_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.14768"},{"key":"e_1_2_9_52_1","doi-asserted-by":"publisher","DOI":"10.1159\/000507218"},{"key":"e_1_2_9_53_1","doi-asserted-by":"publisher","DOI":"10.1111\/all.13345"},{"key":"e_1_2_9_54_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaip.2019.08.025"},{"key":"e_1_2_9_55_1","doi-asserted-by":"publisher","DOI":"10.4168\/aair.2021.13.2.206"},{"key":"e_1_2_9_56_1","doi-asserted-by":"publisher","DOI":"10.1111\/all.13949"},{"key":"e_1_2_9_57_1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.01418"},{"key":"e_1_2_9_58_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrdp.2017.26"},{"key":"e_1_2_9_59_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.16752"},{"key":"e_1_2_9_60_1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.00978"},{"key":"e_1_2_9_61_1","doi-asserted-by":"publisher","DOI":"10.1111\/all.14478"},{"key":"e_1_2_9_62_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41572-020-0149-1"},{"key":"e_1_2_9_63_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00011-020-01381-7"},{"key":"e_1_2_9_64_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11154-016-9328-5"},{"key":"e_1_2_9_65_1","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.139930"},{"key":"e_1_2_9_66_1","doi-asserted-by":"publisher","DOI":"10.2147\/ITT.S240874"},{"key":"e_1_2_9_67_1","doi-asserted-by":"publisher","DOI":"10.1177\/09612033211025095"},{"key":"e_1_2_9_68_1","doi-asserted-by":"publisher","DOI":"10.1080\/14728222.2020.1832464"},{"key":"e_1_2_9_69_1","doi-asserted-by":"publisher","DOI":"10.1038\/nbt.2076"},{"key":"e_1_2_9_70_1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.01862"},{"key":"e_1_2_9_71_1","doi-asserted-by":"publisher","DOI":"10.2147\/CCID.S289716"},{"key":"e_1_2_9_72_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41573-021-00266-6"},{"issue":"4","key":"e_1_2_9_73_1","first-page":"6","article-title":"Dermatologic applications and safety considerations of Janus kinase inhibitors","volume":"25","author":"Svoboda SA","year":"2020","journal-title":"Skin Therapy Lett"},{"key":"e_1_2_9_74_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-019-0602-x"},{"key":"e_1_2_9_75_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)30262-2"},{"key":"e_1_2_9_76_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2020006844"},{"key":"e_1_2_9_77_1","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jmedchem.0c00597"},{"key":"e_1_2_9_78_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-021-01049-7"},{"key":"e_1_2_9_79_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2019-123331"},{"key":"e_1_2_9_80_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-016-0313-y"},{"key":"e_1_2_9_81_1","unstructured":"Ibrutinib prescribing information. Accessed September 6 2021.https:\/\/www.imbruvica.com\/files\/prescribing\u2010information.pdf"},{"key":"e_1_2_9_82_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40257-020-00535-x"},{"key":"e_1_2_9_83_1","doi-asserted-by":"publisher","DOI":"10.1111\/jcmm.14548"},{"key":"e_1_2_9_84_1","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jmedchem.9b01916"},{"key":"e_1_2_9_85_1","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.24310"},{"key":"e_1_2_9_86_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2019-126286"},{"key":"e_1_2_9_87_1","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jmedchem.7b01712"},{"key":"e_1_2_9_88_1","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.13351"},{"key":"e_1_2_9_89_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-020-01318-8"},{"key":"e_1_2_9_90_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbagen.2020.129531"},{"key":"e_1_2_9_91_1","unstructured":"clinicaltrials.gov.Single dose and multiple dose study to assess safety and tolerability of LOU064 (NCT03918980). Accessed July 2 2021.https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03918980?term=LOU064&draw=2&rank=3"},{"key":"e_1_2_9_92_1","unstructured":"MaurerM BergerW et al.The Bruton\u2019s tyrosine kinase inhibitor remibrutinib (LOU064) in chronic spontaneous urticaria: top line results of a phase 2b dose\u2010finding study. Presented at the EADV Congress.2021."},{"key":"e_1_2_9_93_1","unstructured":"clinicaltrials.gov.Dose\u2010finding study to evaluate efficacy and safety of LOU064 in patients With CSU inadequately controlled by H1\u2010antihistamines (NCT03926611). Accessed July 2 2021.https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03926611?term=LOU064&draw=2&rank=5"},{"key":"e_1_2_9_94_1","unstructured":"clinicaltrials.gov.Open\u2010label multicenter extension study to evaluate long\u2010term safety and tolerability of LOU064 in subjects with CSU (NCT04109313). Accessed July 2 2021.https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04109313?term=LOU064&draw=2&rank=1"},{"key":"e_1_2_9_95_1","unstructured":"clinicaltrials.gov.A phase 3 study of efficacy and safety of remibrutinib in the treatment of CSU in adults inadequately controlled by H1 antihistamines (REMIX\u20101) (NCT05030311). Accessed October 11 2021.https:\/\/clinicaltrials.gov\/ct2\/show\/NCT05030311?term=NCT05030311&draw=2&rank=1"},{"key":"e_1_2_9_96_1","unstructured":"clinicaltrials.gov.A safety and efficacy study of remibrutinib in the treatment of CSU in Japanese adults inadequately controlled by H1\u2010antihistamines (REMIX\u2010Japan) (NCT05048342). Accessed October 11 2021.https:\/\/clinicaltrials.gov\/ct2\/show\/NCT05048342?term=NCT05048342&draw=2&rank=1"},{"key":"e_1_2_9_97_1","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.1056"},{"key":"e_1_2_9_98_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-021-01537-w"},{"key":"e_1_2_9_99_1","unstructured":"clinicaltrials.gov.A study to evaluate the long\u2010term safety and efficacy of fenebrutinib in participants previously enrolled in a fenebrutinib chronic spontaneous urticaria (CSU) study (NCT03693625). Accessed July 5 2021.https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03693625?term=fenebrutinib&draw=2&rank=1"},{"key":"e_1_2_9_100_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.41811"},{"key":"e_1_2_9_101_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.20431"},{"key":"e_1_2_9_102_1","unstructured":"clinicaltrials.gov.A study of PRN1008 in patients with pemphigus (NCT03762265). Accessed October 11 2021.https:\/\/clinicaltrials.gov\/ct2\/results?cond=&term=NCT03762265&cntry=&state=&city=&dist="},{"key":"e_1_2_9_103_1","unstructured":"Sanofi provides update on Phase 3 study evaluating rilzabrutinib for the treatment of pemphigus. September 9 2021. Accessed October 1 2021.https:\/\/www.sanofi.com\/en\/media\u2010room\/press\u2010releases\/2021\/2021\u201009\u201009\u201007\u201000\u201000\u20102293920[press release]"},{"key":"e_1_2_9_104_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jdermsci.2021.07.002"},{"key":"e_1_2_9_105_1","unstructured":"clinicaltrials.gov.A study of BMS\u2010986166 or branebrutinib for the treatment of participants with atopic dermatitis (NCT05014438). Accessed October 11 2021.https:\/\/clinicaltrials.gov\/ct2\/show\/NCT05014438?term=NCT05014438&draw=2&rank=1"},{"key":"e_1_2_9_106_1","unstructured":"clinicaltrials.gov.Study to assess safety and effectiveness of branebrutinib treatment in participants with active systemic lupus erythematosus or primary Sj\u00f6gren's syndrome or branebrutinib treatment followed by open\u2010label abatacept treatment in study participants with active rheumatoid arthritis (NCT04186871). Accessed October 11 2021.https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04186871?term=NCT04186871&draw=2&rank=1"},{"key":"e_1_2_9_107_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaip.2020.11.043"},{"key":"e_1_2_9_108_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2018.02.021"},{"key":"e_1_2_9_109_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2017.04.011"},{"key":"e_1_2_9_110_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12016-020-08794-6"},{"key":"e_1_2_9_111_1","doi-asserted-by":"publisher","DOI":"10.23822\/EurAnnACI.1764-1489.132"},{"key":"e_1_2_9_112_1","doi-asserted-by":"publisher","DOI":"10.1080\/14712598.2017.1285903"},{"key":"e_1_2_9_113_1","doi-asserted-by":"publisher","DOI":"10.1080\/1744666X.2019.1562905"},{"key":"e_1_2_9_114_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2017.11.005"},{"key":"e_1_2_9_115_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2011-200831"},{"key":"e_1_2_9_116_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-018-0872-z"},{"key":"e_1_2_9_117_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.medidd.2020.100075"},{"key":"e_1_2_9_118_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41577\u2010021\u201000622\u2010y"},{"key":"e_1_2_9_119_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.16703"},{"key":"e_1_2_9_120_1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.00627"},{"key":"e_1_2_9_121_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2020.03.005"},{"key":"e_1_2_9_122_1","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M110.165613"}],"container-title":["Allergy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/all.15261","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/all.15261","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/all.15261","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,22]],"date-time":"2023-08-22T05:49:37Z","timestamp":1692683377000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/all.15261"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2,28]]},"references-count":121,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2022,8]]}},"alternative-id":["10.1111\/all.15261"],"URL":"https:\/\/doi.org\/10.1111\/all.15261","archive":["Portico"],"relation":{},"ISSN":["0105-4538","1398-9995"],"issn-type":[{"value":"0105-4538","type":"print"},{"value":"1398-9995","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,2,28]]},"assertion":[{"value":"2021-11-16","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-02-14","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-02-28","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}